Broad Institute wins the biggest round of the CRISPR IP battle

The U.S. Patent Trial and Appeals Board closed a second CRISPR-Cas9 interference case in favor of the Broad Institute, giving the companies with access to Broad’s CRISPR IP portfolio a potential upper hand in IP negotiations when CRISPR-Cas9 therapies reach the market.

However, the CRISPR IP landscape is so complex that there may never be one winner in the patent battle...